Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.09 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: ruserontinib, tesevatinib, afatinib +79 | 1.00 |
| trials ClinicalTrials.gov | 14 Parkinson's trials, 1 stopped | 0.94 |
| literature PubMed | 108 Parkinson's papers of 107,953 | 0.38 |
| pathways Reactome | 37 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 2887
Sealed predictions
- EGFR in dopamine neurons, braak-0.10 (p 0.803) → -0.41 (p 0.273)receipt 2894
Swarm cases
receipt 2894: EGFR in dopamine neurons, braak
- power
- full sample -0.20 (p 0.429, n 18), 95% CI -0.61 to +0.30. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.19 (p 0.455, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.25 (p 0.323, n 18). could be the mix.
- skeptic
- leave-one-out range -0.32 to -0.10, sign flips 0; without severely affected donors -0.20 (p 0.429, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for EGFR in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts